10-K: TriSalus Life Sciences, Inc. 2023 Annual Report: Navigating Growth and Challenges in Oncology Innovation

TriSalus Life Sciences, Inc. reports progress in its innovative oncology platform, combining drug delivery technology with immunotherapy for liver and pancreatic cancers, while facing financial challenges and navigating a complex regulatory environment.

Summary

• TriSalus Life Sciences, Inc. is focused on developing an oncology platform that combines drug delivery technology with immunotherapy to treat liver and pancreatic cancers.
• The company's PEDD technology, including the TriNav Infusion System, aims to overcome barriers like high intratumoral pressure that can limit drug effectiveness.
• TriNav, a 510(k) cleared device, generated $18.5 million in revenue in 2023, with a 77% growth in the fourth quarter compared to the previous year.
• The company is also developing nelitolimod, an investigational immunotherapeutic, and conducting Phase 1 clinical trials for various indications.
• TriSalus reported a net loss of $59.0 million in 2023 and $47.2 million in 2022, with an accumulated deficit of $248.4 million as of December 31, 2023.
• The company's independent auditors and management have expressed substantial doubt about its ability to continue as a going concern due to ongoing losses and the need for additional capital.
• TriSalus completed a business combination with MedTech Acquisition Corporation in August 2023, raising $36.9 million in net proceeds.
• The company is exploring strategic options, including partnerships and potential expedited regulatory pathways, to advance its product candidates and achieve commercial success.

Sentiment

Score: 4

Explanation: The company faces significant financial challenges and uncertainty regarding its ability to continue as a going concern, but there are positive developments in TriNav revenue growth and clinical data, as well as potential for future growth through nelitolimod and strategic partnerships.

Positives

• TriNav revenue growth of 77% in Q4 2023 compared to the previous year demonstrates increasing market adoption.
• Positive results from the HEOR study suggest TriNav's effectiveness in treating complex patients with a high burden of disease.
• Receipt of a unique and permanent HCPCS code from CMS ensures continued reimbursement for TriNav.
• Collaboration with leading cancer centers like MD Anderson Cancer Center provides access to expertise and resources.
• Potential for international expansion through distribution partnerships, such as the one with Hangzhou in China.
• Ongoing development of nelitolimod and exploration of additional indications for TriNav offer future growth opportunities.
• The company's focus on addressing unmet medical needs in liver and pancreatic cancers positions it in a large and growing market.

Negatives

• The company has a history of significant operating losses, with a net loss of $59.0 million in 2023 and an accumulated deficit of $248.4 million.
• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing losses and the need for additional capital.
• The company's near-term success is highly dependent on the continued market acceptance and adoption of TriNav.
• The reimbursement environment for TriNav is uncertain beyond 2024, and any changes could negatively impact sales.
• The company has a limited marketing, sales, and distribution organization compared to larger competitors.
• Nelitolimod is in early clinical development, and its success is uncertain and dependent on regulatory approval.
• The company faces intense competition from established pharmaceutical, biotechnology, and medical device companies.

Risks

• The company's ability to continue as a going concern is uncertain, and it may be unable to raise sufficient capital to fund operations.
• The Dynavax Agreement requires significant milestone and royalty payments, potentially impacting the company's financial resources.
• Failure to achieve continued market acceptance of TriNav or secure favorable reimbursement could harm the company's business and prospects.
• Clinical development of nelitolimod is lengthy, expensive, and uncertain, with no guarantee of success.
• The company may face challenges in competing with larger, more established companies in the industry.
• Failure to obtain, protect, maintain, or enforce intellectual property rights could harm the company's competitive position.
• The company is subject to extensive and complex regulatory requirements, and failure to comply could result in penalties and restrictions.
• The complexity of combination products presents unique development and regulatory challenges.
• The company's reliance on third-party manufacturers and suppliers exposes it to supply chain risks.
• The company's stock price has been volatile and may continue to be so in the future.
• Changes in healthcare laws and regulations, including reimbursement policies, could adversely affect the company's business.

Future Outlook

The company plans to continue investing in the commercialization of TriNav, advancing the clinical development of nelitolimod, and exploring potential expedited regulatory pathways. Future success depends on factors such as market adoption, clinical trial outcomes, regulatory approvals, and securing additional funding.

Industry Context

TriSalus is operating in the rapidly growing oncology market, specifically targeting difficult-to-treat liver and pancreatic cancers. The company's approach of combining drug delivery technology with immunotherapy aligns with broader industry trends focused on personalized medicine and improving drug efficacy. The success of TriNav and nelitolimod will depend on their ability to demonstrate superior outcomes compared to existing treatments and gain acceptance among physicians and payers.

Comparison to Industry Standards

• Compared to standard microcatheters, TriNav has demonstrated improved therapy delivery in both TARE and TACE studies, as well as in real-world data from the HEOR study.
• In a retrospective study, TriNav achieved a significantly higher objective response rate (100% vs. 76.5%) and improved pathological response (88.8% vs. 33.8%) compared to standard microcatheters in treating solitary HCC tumors.
• In TACE procedures, interventional radiologists were able to deliver significantly more chemotherapeutic to the tumor when using TriNav vs. the amount delivered using standard catheters.
• TriNav patients had fewer 30-day inpatient visits post-procedure vs. non-TriNav patients in matched cohort comparison.
• TriNav HCC patients were more likely to have a liver transplant in matched cohort comparison.
• TriNav TARE patients with liver metastases had fewer clinical complications post-procedure vs. non-TriNav patients in matched cohort comparison.
• TriNav TARE patients with liver metastases had lower rates of post-procedure fatigue vs. non-TriNav patients.
• The company's competitors in the drug delivery space include manufacturers of standard microcatheters, as well as companies like Embolx (Sniper) and Guerbet (SeQure).
• In the immunotherapy space for liver and pancreatic cancers, nelitolimod will compete with existing and investigational therapies, including checkpoint inhibitors and targeted therapies from companies like AstraZeneca, Roche, and others.

Related Party Transactions

• In connection with the execution of the Merger Agreement, MTAC entered into the Sponsor Support Agreement with the Sponsor Holders and Legacy TriSalus.
• Pursuant to the Sponsor Support Agreement, 3,125,000 Sponsor Earnout Shares became unvested and subject to potential forfeiture.
• Legacy TriSalus agreed to pay for 50% of the Sponsors contributions into the Trust Account as part of the Merger Agreement.
• The Company engaged Ceros, an SEC registered broker/dealer, to act as placement agent for the non-institutional equity financing component of the Future PIPE Investment. Christopher Dewey, the former Chief Executive Officer and director of MTAC, is a Managing Director of Ceros.
• The Company issued an unsecured promissory note to the Sponsor in December 2022, which was repaid at the Closing of the Business Combination.
• The Company entered into indemnification agreements with its executive officers and directors.
• Several executive officers and directors participated in the Series B-2/B-3 Preferred Stock Financing, purchasing shares and warrants on the same terms as other investors.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings and capital raises. Uncertainty regarding the company's ability to continue as a going concern. Potential for significant returns if the company's products are successful.
• Employees: Potential impact on job security if the company is unable to raise sufficient capital or achieve profitability. Opportunity to participate in the company's growth through equity awards.
• Customers: Potential for improved treatment options for liver and pancreatic cancers if TriNav and nelitolimod are successful. Uncertainty regarding the availability and pricing of products if the company faces financial difficulties.
• Suppliers: Potential impact on business relationships if the company is unable to meet its financial obligations or if there are disruptions in the supply chain.
• Creditors: Risk of default if the company is unable to generate sufficient cash flow or raise additional capital to meet its obligations.

Next Steps

• Release of PERIO-01 Phase 1 overall survival and progression free survival data, with optimal biologic dose confirmation, in Q2 2024.
• PERIO-03 Phase 1 (monotherapy) enrollment completion and data release in Q4 2024 with initiation of Phase 1b (+ CPI).
• PERIO-02 data release and initiation of next-phase enrollment in 2H 2024.
• Complete market evaluation of TriNav Large and launch commercially in the second half of 2024.
• Continue to progress clinical evidence of the value of PEDD through TriSalus-sponsored and investigator-sponsored research.
• Seek potential expedited development pathway or accelerated approval regulatory pathway for nelitolimod.
• Conduct clinical trials with checkpoint inhibitors.
• Expand TriNav sales organization in the U.S.
• Consider expanding internationally through distributors.
• Develop collaborations with therapeutic partners.
• Continue partnering with leading academic medical centers.

Key Dates

Keywords

Oncology, Drug Delivery, Immunotherapy, Liver Cancer, Pancreatic Cancer, PEDD, TriNav, Nelitolimod, TARE, TACE, Clinical Trials, FDA, Medical Device, Biotechnology, Intratumoral Pressure, Immunosuppression, Healthcare Reimbursement, Interventional Radiology